Metrics as of 10/17/2026, 12:30 AM (Berlin time), refresh in progress.
Haleon Stock
Haleon plc
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United Kingdom
- CEO
- Brian James McNamara
- Employees
- 24,535
- Market cap
- $44.5 B
- IPO
- 25/07/2022
Haleon plc is a significant global entity in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company's business model encompasses the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. Its…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Haleon stock: price history
1D
+1.9%
1W
+8.7%
1M
+10.0%
6M
+3.9%
YTD
+0.2%
1Y
+10.1%
2Y
+0.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
04/03/2027 (in 138 days)
Volatility around earnings
~33% stronger price swings than usual
Haleon stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Haleon
Analyst assessment of Haleon
PRICE TARGET LOW
US$10.20
CONSENSUS
US$10.20
MEDIAN
US$10.20
PRICE TARGET HIGH
US$10.20
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 23/01/2026
Haleon stock metrics
P/E
20.68
P/B
2.04
EV/EBITDA
13.85
RETURN ON EQUITY
4.7%
NET MARGIN
13.6%
DEBT/EQUITY
0.5
DIVIDEND YIELD
1.9%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
100.5%
FLOAT SHARES
4,421,202,505
AVG. DAILY VOLUME (30D)
19,863,962
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +1.9%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Haleon stock
What does Haleon do?
Haleon plc is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United Kingdom.
The CEO is Brian James McNamara, the company employs around 24,535 people.
The IPO was on 25/07/2022; the stock trades on NYSE under the ticker HLN.
What do analysts say about Haleon stock?
4 analysts rate the stock, the consensus is Buy (as of 23/01/2026).
The average price target is US$10.20, ranging from US$10.20 to US$10.20, with a median of US$10.20.
This is an external assessment, not a statement by Market Jury.
When does Haleon report next?
The next earnings date is 04/03/2027.
Around past earnings, price swings were roughly 33% stronger than usual.
Does Haleon pay a dividend?
Yes. The last dividend was US$0.06 per share, ex-date 14/08/2026, paid on 17/09/2026.
The dividend yield is 1.9% (as of 30/06/2026).
Which stocks are comparable to Haleon?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Haleon stock analyzed?
Clicking "Analyze stock" lets five strategies assess Haleon against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.